1. Scrip
  2. >>R&D
  3. >>Clinical Trials

AstraZeneca Takes First Step For Lynparza/Imfinzi Combo In Ovarian Cancer

First PARP plus PD1/L1-inhibitor Combo Data

 
• By Alexandra Shimmings

Combining a PARP inhibitor with a checkpoint inhibitor could improve outcomes in ovarian cancer patients, hint the early data from AstraZeneca’s Phase III DUO-O study of Lynparza and Imfinzi. How much broader a market now beckons for the two drugs remains uncertain, however.    

Female Reproductive System_1200
• Source: Shutterstock

A first look at the data from the Phase III DUO-O study of AstraZeneca PLC’s Lynparza and Imfinzi in newly diagnosed ovarian cancer suggest the combination could have benefit in delaying disease progression, but its commercial potential is likely to depend on upcoming overall survival and subgroup data.

The DUO-O trial is testing the PARP inhibitor Lynparza (olaparib) with the anti-PD-L1 Imfinzi (durvalumab) together with the VEGF inhibitor...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Schrödinger Drops CDC7 Inhibitor SGR-2921 After Two Patient Deaths

 
• By Alaric DeArment

The drug is one of multiple candidates in the class that have been pulled from development, though it is not the company’s lead candidate.

Vedanta’s Live Bacteria Reach A Dead End In Ulcerative Colitis

 
• By Andrew McConaghie

The microbiome-based company’s trial of VE202 in ulcerative colitis has failed in Phase II, but its ongoing Phase III study in C difficile infection is more promising.

Xenon Nears Phase III Readout For Potential Epilepsy And Depression Blockbuster

 
• By Andrew McConaghie

Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.

Another Day Another Win For Novartis’s Ianalumab – This Time In ITP

 
• By Aakash Babu

The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.

More from R&D

Another Day Another Win For Novartis’s Ianalumab – This Time In ITP

 
• By Aakash Babu

The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 
• By Alaric DeArment

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.

IO Biotech Plans Cylembio Filing Despite ‘Narrowly Missed’ Phase III Endpoint

 
• By Mandy Jackson

The company plans to meet with the US FDA prior to submitting a BLA before the end of 2025 for its cancer vaccine as a first-line advanced melanoma treatment in combination with Keytruda.